VRDN - Viridian Therapeutics, Inc.\DE

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 14.9

Open

$ 14.83

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 14.42 - $ 15.24

52 Week Range

$ 10.93 - $ 28.35

Volume

1,013,501

Average Volume

Market Cap

910.38M

Beta (5Y Monthly)

$ 0.25

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-10-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-14-2022	09-30-2022	10-Q
8	08-15-2022	06-30-2022	10-Q
9	05-13-2022	03-31-2022	10-Q
10	03-11-2022	12-31-2021	10-K
11	11-05-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-07-2021	03-31-2021	10-Q
14	03-26-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-08-2020	03-31-2020	10-Q
18	03-13-2020	12-31-2019	10-K
19	11-08-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-09-2019	03-31-2019	10-Q
22	03-14-2019	12-31-2018	10-K
23	11-07-2018	09-30-2018	10-Q
24	08-08-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-15-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-11-2017	06-30-2017	10-Q
29	05-11-2017	03-31-2017	10-Q
30	03-24-2017	12-31-2016	10-K
31	10-26-2016	09-30-2016	10-Q
32	08-15-2016	06-30-2016	10-Q
33	05-16-2016	03-31-2016	10-Q
34	03-21-2016	12-31-2015	10-K
35	11-13-2015	09-30-2015	10-Q
36	08-14-2015	06-30-2015	10-Q
37	05-15-2015	03-31-2015	10-Q
38	03-27-2015	12-31-2014	10-K
39	11-14-2014	09-30-2014	10-Q
40	08-14-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Viridian Therapeutics Q1 2024 GAAP EPS $(0...
05/08/2024 11:05:06

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of...

B. Riley Securities Maintains Buy on Virid...
03/21/2024 14:05:06

B. Riley Securities analyst Kalpit Patel maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price targe...

Unveiling 4 Analyst Insights On Viridian T...
03/20/2024 18:00:30

Needham Maintains Buy on Viridian Therapeu...
03/20/2024 17:07:59

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

HC Wainwright & Co. Reiterates Buy on Viri...
02/29/2024 20:19:46

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $37 pri...

Navigating 6 Analyst Ratings For Viridian ...
02/28/2024 14:00:16

Wedbush Maintains Outperform on Viridian T...
02/28/2024 13:07:11

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from...

Needham Reiterates Buy on Viridian Therape...
02/28/2024 12:32:49

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

Viridian Therapeutics Q4 2023 GAAP EPS $(1...
02/27/2024 22:14:10

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.35) per share which missed the analyst consensus estimate ...

heres-why-viridian-therapeutics-vrdn-stock-is-moving

Here's Why Viridian Therapeutics (VRDN) St...
01/18/2024 14:51:04

Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten publi...

Viridian Therapeutics Prices $150M Public ...
01/18/2024 07:14:07

Viridian is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. In addition, Vi...

Viridian Therapeutics Announces Proposed U...
01/17/2024 21:01:41

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-clas...

Viridian Therapeutics To Provide Key Updat...
01/08/2024 13:17:39

Thyroid Eye Disease Portfolio: VRDN-001 and VRDN-003Intravenous VRDN-001Viridian's lead product candidate, VRDN-001, is a m...

Oppenheimer Maintains Outperform on Viridi...
12/19/2023 13:10:42

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price tar...

HC Wainwright & Co. Reiterates Buy on Viri...
12/18/2023 17:20:23

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $37 pri...

zimvie-agrees-to-sell-its-spine-business-joins-united-states-steel-pgt-innovations-and-other-big-stocks-moving-higher-on-monday

ZimVie Agrees To Sell Its Spine Business, ...
12/18/2023 15:57:14

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

Viridian Therapeutics Announces Clinical D...
12/18/2023 12:14:19

RBC Capital Reiterates Outperform on Virid...
12/14/2023 15:39:05

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price t...

Analyst Ratings for Viridian Therapeutics
12/04/2023 15:00:44

Wedbush Reiterates Outperform on Viridian ...
12/04/2023 13:34:18

Wedbush analyst Laura Chico reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $37 price target.